STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its ...
The US Food and Drug Administration (FDA) released a draft guidance on April 3 providing recommendations to sponsors and testing sites on data integrity for bioavailability and bioequivalence (BA/BE) ...
LA ROCHELLE, France--(BUSINESS WIRE)--Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, with a commercial ...
Divalproex is available as 125, 250 and 500mg tablets. Therefore, the possible divalproex total daily dosage regimens are in increments of 125mg. Table IV shows that all divalproex dosage regimens, ...
Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in rat and dog pharmacokinetic (PK) studies while significant ...
The US Food and Drug Administration (FDA) has published a final guidance on the bioavailability (BA) data drug sponsors should include in their premarket applications. The guidance has been several ...
The US Food and Drug Administration (FDA) on Monday published two new draft guidance documents providing recommendations to sponsors planning to conduct food-effect (FE) studies for orally ...
BeOne Medicines ((ONC)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...
Researchers at the University of Seville’s Food Colour and Quality Laboratory have studied the effects of different cooking methods used for tomatoes and carrots (in the oven, microwave or air fryer, ...
CN Bio and Altis Biosystems, Inc. (“Altis”), leading developers of in vitro human organ models that optimize the accuracy and efficiency of drug development, today announced a strategic partnership.
Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. STOCKHOLM--(BUSINESS WIRE)-- Xspray Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results